Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
Christine M. Eischen, PhD
Advertisement
Articles by Christine M. Eischen, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Epcoritamab Combo in R/R Follicular Lymphoma
2
Giredestrant Exhibits DFS Improvement in Early-Stage Breast Cancer
3
How Does NALIRIFOX Fit Into the Metastatic PDAC Treatment Paradigm?
4
NALIRIFOX Shows Survival Benefit Vs Gemcitabine/Nab-Paclitaxel in Metastatic PDAC
5
